AGLE Aeglea BioTherapeutics Inc.

8.01
-0.34  -4%
Previous Close 8.35
Open 8.3
Price To Book 3.01
Market Cap 191936533
Shares 23,962,114
Volume 23,784
Short Ratio
Av. Daily Volume 163,918

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
AEB1102
Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS)
Phase 1/2 repeat dose data due 1H 2019. Phase 3 trial to be initiated 2Q 2019 with data due 1Q 2021.
Pegzilarginase (AEB1102)
Arginase I deficiency
Phase 1 dose escalation data presented at AACR April 15, 2018.
AEB1102
Solid tumors
Phase 1 data presented at ESMO October 2018 noted 1/28 PRs and 8/23 SD.
Pegzilarginase (AEB1102)
Solid tumors
Phase 1/2 top-line safety and clinical data due 1Q 2019.
Pegzilarginase (AEB1102) + KEYTRUDA
Small cell lung cancer (SCLC)